NO20071005L - Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer - Google Patents

Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer

Info

Publication number
NO20071005L
NO20071005L NO20071005A NO20071005A NO20071005L NO 20071005 L NO20071005 L NO 20071005L NO 20071005 A NO20071005 A NO 20071005A NO 20071005 A NO20071005 A NO 20071005A NO 20071005 L NO20071005 L NO 20071005L
Authority
NO
Norway
Prior art keywords
cancer
pyrimidones
enantiomers
prevention
applications
Prior art date
Application number
NO20071005A
Other languages
English (en)
Inventor
Michael Howard Block
Jayachandran Ezhuthachan
Brian Aquila
Audrey Davies
Timothy Pontz
Maria-Elena Theoclitou
Xiaolan Zheng
Daniel John Russell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37904998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071005(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2005/003207 external-priority patent/WO2006018628A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20071005L publication Critical patent/NO20071005L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår nye forbindelser som har strukturell formel (I) og deres farmasøytiske preparater og fremgangsmåter for anvendelse derav. Disse nye forbindelsene kan anvendes for behandling eller forebygging av kreft.
NO20071005A 2004-08-18 2007-02-21 Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer NO20071005L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60236604P 2004-08-18 2004-08-18
PCT/GB2005/003207 WO2006018628A1 (en) 2003-03-07 2005-08-16 Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer

Publications (1)

Publication Number Publication Date
NO20071005L true NO20071005L (no) 2007-05-16

Family

ID=37904998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071005A NO20071005L (no) 2004-08-18 2007-02-21 Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer

Country Status (18)

Country Link
US (3) US20080293744A1 (no)
EP (1) EP1781674A1 (no)
JP (1) JP2008509977A (no)
KR (1) KR20070046176A (no)
CN (1) CN101027309B (no)
AU (1) AU2005273705B8 (no)
BR (1) BRPI0514390A (no)
CA (1) CA2575188A1 (no)
IL (1) IL180810A0 (no)
MX (1) MX2007001953A (no)
MY (1) MY141233A (no)
NO (1) NO20071005L (no)
RU (1) RU2447077C2 (no)
SA (1) SA05260258B1 (no)
TW (1) TW200616977A (no)
UA (1) UA89201C2 (no)
UY (1) UY29070A1 (no)
ZA (1) ZA200701082B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101952292A (zh) * 2007-11-13 2011-01-19 艾科斯有限公司 人磷脂酰肌醇3-激酶δ的抑制剂
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
PT3513793T (pt) 2011-09-02 2021-05-10 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201907576SA (en) 2015-02-27 2019-09-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2024103067A1 (en) * 2022-11-10 2024-05-16 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
PT888359E (pt) 1996-03-11 2002-10-31 Syngenta Participations Ag Derivados de pirimidin-4-ona como pesticida
NZ511674A (en) 1998-12-23 2003-11-28 Du Pont Pharm Co Nitrogen containing heterobicycles as factor Xa inhibitors
JP4994552B2 (ja) 1999-09-16 2012-08-08 キュリス，インコーポレイテッド ヘッジホッグシグナル伝達経路のメディエーター、組成物及びそれらと関連する利用
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
CZ20021428A3 (cs) 1999-10-27 2002-11-13 Cytokinetics, Inc. Způsoby a kompozice vyuľívající chinazoliny
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
MXPA03008691A (es) 2001-03-29 2003-12-12 Bristol Myers Squibb Co Metodo para tratamiento de enfermedades proliperativas usando inhibidores eg5.
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP1383771A1 (en) 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
JP2005511581A (ja) * 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
CA2468156A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Azolopyrimidinone compounds and their use
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
WO2003049527A2 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2467722A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Thienopyrimidinone derivatives as mitotic kinesin inhibitors
US20050107404A1 (en) * 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
JP2005529076A (ja) 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
NZ536190A (en) 2002-04-17 2007-08-31 Cytokinetics Inc Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP
RU2004135554A (ru) * 2002-05-09 2006-01-20 Цитокинетикс, Инк. (Us) Пиримидиноны, композиции на их основе и способы их использования
EP1553931A4 (en) * 2002-05-09 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1517904A4 (en) 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
DE60326248D1 (de) * 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
WO2004018058A2 (en) 2002-08-21 2004-03-04 Cytokinetics, Inc. Compounds, compositions, and methods
EP1554265A4 (en) 2002-09-13 2008-05-07 Cytokinetics Inc COMPOSITIONS, COMPOSITIONS AND M THODES
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
BR0315247A (pt) 2002-10-11 2005-08-30 Cytokinetics Inc Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
AU2003300031A1 (en) 2002-10-11 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004064741A2 (en) 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
AR050920A1 (es) 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
NZ542227A (en) 2003-03-07 2008-12-24 Astrazeneca Ab Novel fused heterocycles and uses thereof
JP2006523232A (ja) 2003-04-10 2006-10-12 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
EP1620092A4 (en) 2003-05-07 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1622613A4 (en) 2003-05-14 2008-04-02 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US20070032536A1 (en) 2003-05-15 2007-02-08 Xianping Qian Compounds, compositions and methods
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
CN1809563A (zh) * 2003-06-20 2006-07-26 希龙公司 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
US20050165089A1 (en) * 2003-10-06 2005-07-28 Gustave Bergnes Compounds, compositions and methods
JP2007510660A (ja) * 2003-11-07 2007-04-26 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
KR20060127413A (ko) 2003-11-25 2006-12-12 카이론 코포레이션 항암제로서의 퀴나졸리논 화합물
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
RU2006138864A (ru) * 2004-04-06 2008-05-20 Чирон Корпорейшн (Us) Ингибиторы митотического кинезина
ES2311992T3 (es) 2004-05-21 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.
BRPI0510929A (pt) 2004-06-18 2007-07-17 Chiron Corp derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer
KR20070046175A (ko) 2004-08-18 2007-05-02 아스트라제네카 아베 선택된 융합 복소환 및 이의 용도
US20060041128A1 (en) 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
EP2275412A1 (en) * 2004-10-19 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives

Also Published As

Publication number Publication date
BRPI0514390A (pt) 2008-06-10
US7498333B2 (en) 2009-03-03
UA89201C2 (ru) 2010-01-11
JP2008509977A (ja) 2008-04-03
UY29070A1 (es) 2006-03-31
CN101027309B (zh) 2010-10-27
KR20070046176A (ko) 2007-05-02
ZA200701082B (en) 2008-07-30
AU2005273705B8 (en) 2010-01-28
TW200616977A (en) 2006-06-01
US20060041129A1 (en) 2006-02-23
IL180810A0 (en) 2007-06-03
RU2447077C2 (ru) 2012-04-10
SA05260258B1 (ar) 2009-12-22
CA2575188A1 (en) 2006-02-23
AU2005273705A1 (en) 2006-02-23
RU2007109866A (ru) 2008-09-27
MX2007001953A (es) 2007-05-09
AU2005273705B2 (en) 2009-12-10
CN101027309A (zh) 2007-08-29
US20080293744A1 (en) 2008-11-27
EP1781674A1 (en) 2007-05-09
US20090099210A1 (en) 2009-04-16
MY141233A (en) 2010-03-31

Similar Documents

Publication Publication Date Title
NO20071005L (no) Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
SA521422270B1 (ar) Apol1 مثبطات لـ وطرق لاستخدامها
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
NO20081454L (no) Met-kinaseinhibitorer
EA201370122A1 (ru) Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
NO20061197L (no) Proteasominhibitorer og fremgangsmater for anvendelse av samme
NO20071521L (no) Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase
DE60331219D1 (de) Azaindole als hemmstoffe von c-jun n-terminalen kinasen
DE602007012363D1 (de) 2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20083568L (no) Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
EA200870391A1 (ru) Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20060230L (no) Nye aminobenzofenonforbindelser
NO20085212L (no) Nye pyridinanaloger
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
NO20091353L (no) Serine hydrolaseinhibitorer
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application